2-(4-Benzylphenoxy)-N,N-diethylethylamine hydrochloride
2-(4-Benzylphenoxy)-N,N-diethylethylamine hydrochloride structure
|
Common Name | 2-(4-Benzylphenoxy)-N,N-diethylethylamine hydrochloride | ||
|---|---|---|---|---|
| CAS Number | 92981-78-7 | Molecular Weight | 603.97300 | |
| Density | N/A | Boiling Point | 397ºC at 760 mmHg | |
| Molecular Formula | C6H12N2NaO12P4Sm---- | Melting Point | N/A | |
| MSDS | USA | Flash Point | 116.8ºC | |
|
Enhancement of antitumour activity of cisplatin by N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine. HCl in human ovarian cancer cells with intrinsic or acquired resistance to cisplatin.
Eur. J. Cancer 33(1) , 122-8, (1997) This study was designed to the elucidate sensitising effects of the intracellular histamine antagonist, N,N-diethyl-2[4-(phenylmethyl)phenoxy] ethanamine HCl (DPPE) on the antitumour activity of cis-diamminedichloroplatinum (II) (CDDP) using human ovarian can... |
|
|
Effect of alpha-FMH and DPPE on colony-forming properties of human peripheral progenitor cells.
Curr. Med. Chem. 9(14) , 1349-57, (2002) Endogenous histamine regulates the haematopoiesis. Histidine decarboxylase inhibitor decreases the histamine level, and its intracellular antagonist decreases the histamine effect. The effect of histidine decarboxylase inhibitor (alpha-fluoromethyl histidine)... |
|
|
Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats.
J. Pharm. Pharmacol. 62(8) , 1084-8, (2010) It has been reported that docetaxel is a P-glycoprotein substrate and is metabolized via the cytochrome P450 (CYP) 3A subfamily in rats. Tesmilifene is a substrate of the CYP3A subfamily and is an inhibitor of P-glycoprotein. Thus, the effects of various dose... |
|
|
Effects of N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine on the blood-brain barrier permeability in the rat.
Eur. J. Pharmacol. 387(1) , 63-72, (2000) Histamine plays a role in the regulation of the blood-brain barrier function. In this study, effects of N, N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine (DPPE), an intracellular histamine binding site antagonist on the cerebrovascular permeability were inve... |
|
|
Cerebral ischemia reperfusion-induced vasogenic brain edema formation in rats: effect of an intracellular histamine receptor antagonist.
Eur. J. Pediatr. Surg. 8(4) , 216-9, (1998) Resuscitation in pediatric emergency and some neurological interventions may result in ischemia reperfusion-induced cerebral injuries. Histamine is one of the well established mediators of cerebral swelling and H1- and H2-receptor antagonists could prevent th... |
|
|
Tesmilifene may enhance breast cancer chemotherapy by killing a clone of aggressive, multi-drug resistant cells through its action on the p-glycoprotein pump.
Med. Hypotheses 66(4) , 715-31, (2006) Tesmilifene is a novel potentiator of chemotherapy which, when added to doxorubicin, achieved an unexpected and very large survival advantage over doxorubicin alone in a randomized trial in advanced breast cancer. This trial was unusual in that the early endp... |
|
|
N,N-diethyl-2-[4-(phenylmethyl) phenoxy] ethanamine (DPPE; tesmilifene), a chemopotentiating agent with hormetic effects on DNA synthesis in vitro, may improve survival in patients with metastatic breast cancer.
Hum. Exp. Toxicol. 27(2) , 143-7, (2008) N,N-diethyl-2-[4-(phenylmethyl) phenoxy] ethanamine (DPPE; tesmilifene) is a novel anti-histaminic and chemopotentiating agent that has a hormetic effect on DNA synthesis in MCF (Michigan Cancer Foundation)-7 human breast cancer cells in vitro and stimulates ... |
|
|
Histidine decarboxylase and intracellular histamine in melanoma cells and in a T cell line.
Inflamm. Res. 46 Suppl 1 , S51-2, (1997)
|
|
|
Combined effects of cisplatin and N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine HCl on the growth of human ovarian cancer xenografts in nude mice.
Eur. J. Cancer 33(11) , 1904-5, (1997)
|
|
|
Phase II trial of N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl and doxorubicin chemotherapy in metastatic breast cancer: A National Cancer Institute of Canada clinical trials group study.
J. Clin. Oncol. 17(11) , 3431-7, (1999) This multicenter phase II trial investigated the efficacy and toxicity of a combination of the novel intracellular histamine antagonist, N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl (DPPE), and doxorubicin in patients with anthracycline-naïve metasta... |